Welcome to our dedicated page for Nu Skin Enter SEC filings (Ticker: NUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nu Skin Enterprises, Inc. (NYSE: NUS) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its integrated beauty and wellness operations. These SEC filings cover the performance of the Nu Skin and Rhyz businesses, including revenue, margins, segment results and key metrics such as Customers, Paid Affiliates and Sales Leaders in the core Nu Skin business.
Among the most important filings for NUS are its annual reports on Form 10-K, which describe the company’s business model, risk factors, segment structure, accounting policies and long-term trends, and its quarterly reports on Form 10-Q, which update investors on interim financial performance and regional results. Nu Skin also uses Form 8-K to report material events, such as the release of quarterly and year-to-date financial results, including revenue, earnings per share, non-GAAP measures like constant-currency revenue change and adjusted EPS, and commentary on operating conditions.
In addition, investors can review proxy statements for information on governance and executive compensation, and Form 4 filings to track insider transactions by directors and officers. These documents help clarify how Nu Skin’s leadership and affiliate-driven model align with shareholder interests.
On this page, Stock Titan provides real-time access to Nu Skin’s latest SEC filings as they are posted to EDGAR, along with AI-powered summaries that explain the key points in clear language. Instead of reading entire multi-hundred-page 10-Ks or detailed 10-Qs, you can use these summaries to understand segment performance, changes in margins, updates on initiatives such as Prysm iO and regional expansion, and other material disclosures. Filings related to non-GAAP measures, restructuring and gains or losses from business sales are also highlighted so you can see how they affect reported results.
Nu Skin Enterprises (NUS) filing a Form 144 notifies the SEC of a proposed sale of 20,000 Class A shares through Fidelity Brokerage Services on the NYSE, with an aggregate market value of $239,433.56 and approximately 49,497,715 Class A shares outstanding. The securities listed were acquired as restricted stock vesting from the issuer on multiple dates between 02/15/2022 and 02/15/2024, with individual lot sizes shown. The filer reports no securities sold in the past three months and affirms they possess no undisclosed material adverse information about the issuer. The notice includes required signature and legal attestation language.
Daniel W. Campbell, a director of Nu Skin Enterprises (NUS), reported open-market sales of Class A common stock on 08/29/2025. The filing shows two disposal transactions: 9,046 shares sold at a weighted-average price of $12.12 and 23,391 shares sold at a weighted-average price of $12.10, for total reported disposals of 32,437 shares. After the transactions the report shows 39,216 shares held directly and 53,375 shares held indirectly, including shares held by an irrevocable family trust and by a limited liability company controlled by the reporting person and his spouse.
Form 144 filed for NuSkin Enterprises, Inc. (NUS) reports a proposed sale of 23,391 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $283,117.65. The filing lists the approximate date of sale as 08/29/2025 and shows 49,497,715 shares outstanding. All 23,391 shares were acquired as gifts from affiliate Daniel Campbell on 11/02/2021, with donor acquisition dates and per-lot amounts totaling the 23,391 shares. The filer reports "Nothing to Report" for securities sold in the past three months and includes the standard representation that no undisclosed material adverse information about the issuer is known.
Nu Skin Enterprises (NUS) Form 144 filing reports a proposed sale of 9,046 shares of Common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $109,635.71. The shares represent restricted stock that vested under the issuer's registered plan on 04/24/2012 (4,046 shares) and 05/24/2018 (5,000 shares), with cash payment recorded on the respective vesting dates. The filer states there were no securities sold in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.